Phaseline

Companies › Frontier Medicines

Frontier Medicines: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FMC-376
KRAS G12C inhibitor
KRASPhase 1Advanced Solid Tumors With KRAS G12C MutationsOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06244771FMC-376Phase 1Advanced Solid Tumors With KRAS G12C MutationsOncologyOct 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.